Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo ...

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

This article examines FDA guidance on payment and reimbursement for clinical trial participants, with commentary highlighting key considerations for ethical and effective compensation. It clarifies ...

2025 has been a whirlwind year thus far for the life sciences industry as the sector continues to grapple with a diverse set of evolving challenges. The simultaneous impacts of global trade shifts, ...

Artificial intelligence is reshaping drug discovery, but its integration raises critical questions: How do we balance AI-driven insights with data integrity, human expertise, and ethical ...

Novartis is making a major investment in North Carolina’s Research Triangle, committing $771 million across three projects that will strengthen U.S. pharmaceutical manufacturing. The expansion ...

A global diagnostics and contract manufacturing company faced the challenge of harmonizing quality processes across its enterprise while minimizing costs and complexity. Rather than migrating data ...

In the July issue of Life Science Leader, Cliff Mintz wrote a global update on follow-on biologics in unregulated markets, the European Union, and the United States. With intense public debate around ...

On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer.

Q3 2025 delivered meaningful momentum across the gene, cell, and RNA therapy landscape, highlighted by four global approvals. China’s NMPA cleared Hrain Biotechnology’s Hicara CAR-T for large B-cell ...

On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during ...

Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.